Hypercalcemia

Anery A Patel, Laura Graeff-Armas, Meredith Ross, Whitney Goldner

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hypercalcemia is a metabolic complication in some patients with malignancy, often seen in later-stage malignancies, and often predicts a poor prognosis. The most common causes include tumor secretion of parathyroid hormone-related peptide, excess production of 1, 25-dihydroxy vitamin D, and osteolytic cytokine production. However, the etiology is not always mediated by malignancy, and other causes such as PTH-mediated hypercalcemia should be considered. This chapter reviews the etiology of hypercalcemia associated with malignancy and proposed mechanisms. It also discusses appropriate evaluation and treatment strategies.

Original languageEnglish (US)
Title of host publicationAbeloff’s Clinical Oncology
PublisherElsevier
Pages565-571.e1
ISBN (Electronic)9780323476744
DOIs
StatePublished - Jan 1 2019

Keywords

  • Bisphosphonates
  • Denosumab
  • Etiology
  • Hypercalcemia
  • Malignancy
  • Parathyroid hormone-related peptide
  • PTHrP
  • Treatment
  • Vitamin D

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Hypercalcemia'. Together they form a unique fingerprint.

Cite this